CTOs on the Move

Trevena

www.trevena.com

 
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.trevena.com
  • 955 Chesterbrook Boulevard Suite 110
    Chesterbrook, PA USA 19087
  • Phone: 610.354.8840

Executives

Name Title Contact Details

Similar Companies

Bactrin International

Bactrin International is a Belgrade, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reichert Analytical Instruments

Reichert Analytical Instruments is a Depew, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NationalAccessCannabis

We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.

Process Environments

Process Environments is a League City, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADC Therapeutics

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.